Department of Pediatric Hematology and Oncology, SBÜ Van Education and Research Hospital, Van, Turkey.
Department of Biochemistry, Yüzüncü Yıl University, Van, Turkey.
Arch Pediatr. 2021 May;28(4):296-300. doi: 10.1016/j.arcped.2021.02.009. Epub 2021 Mar 11.
Infantile hemangioma (IH) is a common vascular tumor in children. It is reported that IHs are associated with immunochemical markers such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2).
This cross-sectional study focused on pediatric patients with IH. A total of 46 patients (mean age 14.2±21.9 months) with IH and 45 healthy controls (mean age 21.8±15.08 months) were enrolled. Demographic data, clinical findings, and laboratory parameters were recorded. Blood samples were collected. Serum GLUT1, IGF-2, VEGF-A, fibroblast growth factor 1 (FGF1), and angiopoietin 2 levels were assessed by enzyme-linked immunosorbent assay.
Serum GLUT1, IGF-2, and VEGF-A levels were significantly higher in patients with IH than in healthy controls (8.80±4.07pg/mL vs. 5.66±4.34pg/mL, 281.10±84.12pg/mL vs. 234.19±75.38pg/mL, 1196.99±389.34pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.026, p=0.030, and p=0.036). Serum GLUT1, IGF-2, and VEGF-A levels in patients with complicated hemangioma were significantly higher than in healthy controls (9.69±3.94pg/mL vs. 5.66±4.34pg/mL, 289.94±83.18pg/mL vs. 234.19±75.38pg/mL, 1276.22±388.24pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.017, p=0.022, and p=0.011). Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls. Serum FGF1 levels were higher in patients with IH, complicated hemangioma, and hemangioma receiving propranolol treatment than in healthy controls but the difference was not statistically significantly.
Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment. However, further research on larger and different age subgroups is warranted to assess these markers.
婴儿血管瘤（IH）是儿童中常见的血管肿瘤。据报道，IH 与血管内皮生长因子（VEGF-A）、葡萄糖转运蛋白 1 型（GLUT1）和胰岛素样生长因子-2（IGF-2）等免疫化学标志物有关。
本横断面研究关注的是患有 IH 的儿科患者。共纳入 46 例 IH 患儿（平均年龄 14.2±21.9 个月）和 45 例健康对照者（平均年龄 21.8±15.08 个月）。记录人口统计学数据、临床发现和实验室参数。采集血样。通过酶联免疫吸附试验评估血清 GLUT1、IGF-2、VEGF-A、成纤维细胞生长因子 1（FGF1）和血管生成素 2 水平。
与健康对照组相比，IH 患者的血清 GLUT1、IGF-2 和 VEGF-A 水平显著升高（8.80±4.07pg/mL 比 5.66±4.34pg/mL，281.10±84.12pg/mL 比 234.19±75.38pg/mL，1196.99±389.34pg/mL 比 996.99±349.16pg/mL，分别为 p=0.026、p=0.030 和 p=0.036）。伴发复杂血管瘤的 IH 患者的血清 GLUT1、IGF-2 和 VEGF-A 水平显著高于健康对照组（9.69±3.94pg/mL 比 5.66±4.34pg/mL，289.94±83.18pg/mL 比 234.19±75.38pg/mL，1276.22±388.24pg/mL 比 996.99±349.16pg/mL，分别为 p=0.017、p=0.022 和 p=0.011）。接受普萘洛尔治疗的 IH 患者的血清 GLUT1、IGF-2 和 VEGF-A 水平显著高于健康对照组。与健康对照组相比，IH、伴发复杂血管瘤和接受普萘洛尔治疗的血管瘤患者的血清 FGF1 水平更高，但差异无统计学意义。
在患有血管瘤的患者中，血清 GLUT1、IGF-2 和 VEGF-A 水平与疾病严重程度呈正相关，例如，在伴发复杂血管瘤和需要普萘洛尔治疗的血管瘤中。然而，需要进一步对更大和不同年龄亚组的研究来评估这些标志物。
